Novo Nordisk A/S (NVO) vs Sanofi (SNY)
- Novo Nordisk A/S NVO 40.31 +0.02%
- Sanofi SNY 47.04 +0.28%
Novo Nordisk A/S and Sanofi are both Drug Manufacturers General companies. Novo Nordisk A/S is the larger, with a market value of $134.8B against $111.8B — 1.2× the size. Novo Nordisk A/S trades at the lower P/E: 10.1× against 23.3×. Sanofi grew revenue faster over the last twelve months: 26.3% against 11.1%. Novo Nordisk A/S has the higher net margin (34.1% vs 8.27%) and the higher return on invested capital (29.6% vs 7.05%). Both pay a dividend; Sanofi yields more (5.15% vs 4.46%). Across the 23 metrics below, Novo Nordisk A/S leads on 12 and Sanofi on 11.
Valuation
Profitability
| Metric | NVO | SNY | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 80.89% | 73.44% | 73.01% |
| Operating margin | 42.66% | 18.73% | 18.34% |
| Net margin | 34.09% | 8.27% | 7.31% |
| Free cash flow margin | 13.25% | 40.26% | 18.56% |
| Return on equity | 58.84% | 0.00% | 5.80% |
| Return on assets | 20.52% | 3.24% | 2.28% |
| Return on invested capital | 29.63% | 7.05% | 6.26% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack